首页> 外国专利> The Applicant's argumentation according to which none of D1-D3 teaches to perform the second stage with an upper limit in the amount of fully esterified polyols of 85 by weight is acknowledged. Therefore, an inventive step for the claimed matter 1-11 is acknowledged. PARTICLE MIXTURES AND COMPACT PRODUCTS MOLDED THEREOF, AND PRODUCTION THEREOF

The Applicant's argumentation according to which none of D1-D3 teaches to perform the second stage with an upper limit in the amount of fully esterified polyols of 85 by weight is acknowledged. Therefore, an inventive step for the claimed matter 1-11 is acknowledged. PARTICLE MIXTURES AND COMPACT PRODUCTS MOLDED THEREOF, AND PRODUCTION THEREOF

机译:申请人的论点得到认可,根据该论点,D1-D3均未教导以完全酯化的多元醇的重量上限为85%进行第二阶段的操作。因此,确认了所要求保护的事项1-11的创造性。混合成型的颗粒混合物和紧凑型产品及其生产

摘要

The dry blends comprise a powdery or finely-divided active ingredient such as a pharmaceutical, dietary supplement, agricultural chemical, water-treating agent or biocidal agent, and a micronized synthetic polyolefin-based hydrocarbon wax and/or a micronized synthetic polyfluorocarbon wax that is compatible with the active ingredient. Shape-retentive compacted compositions are formed by pressure compacting such blends. Preferred active ingredients are 1,3-dihalo-5,5-dialkylhydantoins and profen pharmaceuticals such as naproxen.
机译:所述干混物包含粉末状或细分的活性成分,例如药物,饮食补充剂,农药,水处理剂或杀生物剂,以及微粉化的基于聚烯烃的合成烃蜡和/或微粉化的合成的多氟烃蜡。与活性成分相容。通过压力压实这种共混物来形成形状保持压实的组合物。优选的活性成分是1,3-二卤-5,5-二烷基乙内酰脲和普罗芬药物,例如萘普生。

著录项

相似文献

  • 专利
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号